Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
作者信息
Le Bourgeois Amandine, Coste-Burel Marianne, Guillaume Thierry, Peterlin Pierre, Garnier Alice, Imbert Berthe-Marie, Drumel Thomas, Mahé Beatrice, Dubruille Viviane, Blin Nicolas, Lok Anne, Touzeau Cyrille, Gastinne Thomas, Tessoulin Benoît, Jullien Maxime, Vantyghem Sophie, Moreau Philippe, Le Gouill Steven, Béné Marie C, Chevallier Patrice
机构信息
Hematology Department, Nantes University Hospital, Nantes, France.
Virology Department, Nantes University Hospital, Nantes, France.
出版信息
Br J Haematol. 2022 Mar;196(5):e38-e40. doi: 10.1111/bjh.17911. Epub 2021 Oct 20.
Abstract
摘要
相似文献
1
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.同种异体移植后接种第三剂BNT162b2抗SARS-CoV-2信使核糖核酸疫苗的益处。
Br J Haematol. 2022 Mar;196(5):e38-e40. doi: 10.1111/bjh.17911. Epub 2021 Oct 20.
2
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.造血干细胞移植患者接种BNT162b2抗SARS-CoV-2 mRNA疫苗后的血清学反应。
Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.
3
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
4
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.异基因造血细胞移植受者接种2剂和3剂SARS-CoV-2 mRNA疫苗后的抗体反应。
Blood. 2022 Jan 6;139(1):134-137. doi: 10.1182/blood.2021014232.
5
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.BNT162b2 mRNA COVID-19 疫苗在造血干细胞移植受者中的免疫原性和安全性。
Br J Haematol. 2022 Feb;196(4):884-891. doi: 10.1111/bjh.17918. Epub 2021 Oct 28.
6
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
7
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.淀粉样变性患者接种BNT162b2疫苗后抗SARS-CoV-2中和抗体的产生动力学及治疗的影响
Am J Hematol. 2022 Jan 1;97(1):E27-E31. doi: 10.1002/ajh.26406. Epub 2021 Nov 23.
8
Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.在先前感染过SARS-CoV-2的医护人员中，接种两剂BNT162b2疫苗后的刺突抗体滴度评估。
Microbiol Spectr. 2021 Dec 22;9(3):e0103621. doi: 10.1128/Spectrum.01036-21. Epub 2021 Nov 10.
9
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
10
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.接种疫苗后血清中针对新冠病毒变异株中和抗体的快速检测
J Mol Cell Biol. 2022 Jan 29;13(12):918-920. doi: 10.1093/jmcb/mjab050.
引用本文的文献
1
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.细胞治疗受者中对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗第三和第四剂的免疫反应：系统评价和荟萃分析。
Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1.
2
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.异基因造血干细胞受者中 SARS-CoV-2 疫苗剂量的疗效：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):393-399. doi: 10.31557/APJCP.2024.25.2.393.
3
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.SARS-CoV-2 疫苗免疫原性减弱与干细胞移植受者的风险因素：一项荟萃分析。
Blood Adv. 2023 Sep 26;7(18):5624-5636. doi: 10.1182/bloodadvances.2023010349.
4
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.异基因造血干细胞移植后早期接种三剂重组 SARS-CoV-2 疫苗：预测高血清学反应的指标——一项前瞻性、单臂研究。
Front Immunol. 2023 Apr 19;14:1169666. doi: 10.3389/fimmu.2023.1169666. eCollection 2023.
5
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.第三剂BNT162b2 mRNA新冠病毒疫苗显著增强异基因造血干细胞移植受者的免疫原性。
Vaccines (Basel). 2023 Mar 31;11(4):775. doi: 10.3390/vaccines11040775.
6
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.COVID-19 时代的异基因造血干细胞移植。
Front Immunol. 2023 Feb 22;14:1100468. doi: 10.3389/fimmu.2023.1100468. eCollection 2023.
7
Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France.法国奥密克戎毒株流行期间接受1剂或2剂mRNA加强针后异基因干细胞移植受者的新冠病毒感染率及严重程度评估
JAMA Netw Open. 2022 Dec 1;5(12):e2247534. doi: 10.1001/jamanetworkopen.2022.47534.
8
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.异基因造血干细胞受者接种一剂或两剂 COVID-19 疫苗加强针后强烈的 SARS-CoV-2 T 细胞反应。
Cells. 2022 Sep 27;11(19):3010. doi: 10.3390/cells11193010.
9
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?对 COVID-19 大流行第一年疫苗接种情况的快速范围综述：我们是需要更多疫苗还是更多时间？
Medicine (Baltimore). 2022 Sep 16;101(37):e30609. doi: 10.1097/MD.0000000000030609.
10
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis.异基因造血干细胞移植（HSCT）或嵌合抗原受体（CAR）T细胞治疗受者中COVID-19疫苗接种的血清学反应及安全性：一项系统评价和荟萃分析
Exp Hematol Oncol. 2022 Aug 16;11(1):46. doi: 10.1186/s40164-022-00299-6.
本文引用的文献
1
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant.异基因造血干细胞移植受者接种 1 剂和 2 剂 BNT162b2 mRNA 疫苗后的安全性和抗体反应。
JAMA Netw Open. 2021 Sep 1;4(9):e2126344. doi: 10.1001/jamanetworkopen.2021.26344.
2
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.异基因造血干细胞移植受者接种第三剂BNT162b2后的抗体反应。
Lancet Haematol. 2021 Oct;8(10):e681-e683. doi: 10.1016/S2352-3026(21)00274-X. Epub 2021 Sep 3.
3
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.移植受者中第三剂mRNA-1273疫苗的随机试验。
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
4
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.实体器官移植受者中第三剂基于抗SARS-CoV-2信使核糖核酸的疫苗加强接种的有效性
Am J Transplant. 2022 Jan;22(1):322-323. doi: 10.1111/ajt.16775. Epub 2021 Aug 31.
5
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
6
A correlate of protection for SARS-CoV-2 vaccines is urgently needed.迫切需要一种针对新冠病毒疫苗的保护相关性指标。
Nat Med. 2021 Jul;27(7):1147-1148. doi: 10.1038/s41591-021-01432-4.
7
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
8
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.异基因造血干细胞移植或基于 CD19 的嵌合抗原受体 T 细胞治疗后患者的 BNT162b2 mRNA COVID-19 疫苗的安全性和免疫原性：一项单中心前瞻性队列研究。
Transplant Cell Ther. 2021 Sep;27(9):788-794. doi: 10.1016/j.jtct.2021.06.024. Epub 2021 Jun 30.
9
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
10
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
Zotero 插件